All Products
Also known as
None commonly used.
Definition
Pharmacomechanical coupling refers to the processes by which drugs interact with mechanical responses in smooth muscle, particularly in the context of cavernosal smooth muscle. This involves the activation of contractile proteins through membrane potential-independent mechanisms. For instance, in canine trachealis muscle, cholinergic contraction, which primarily uses pharmacomechanical coupling, is associated with changes in phosphatidylinositol metabolism, including a decline in the phosphatidylinositol pool, an increase in phosphatidic acid and diacylglycerol pools, and increased incorporation of 32PO4 into phosphatidylinositol. These changes occur during both the development and maintenance of contraction and are independent of membrane depolarization or increases in cytosolic Ca2+ concentration. These findings suggest that phosphatidylinositol turnover may be part of a receptor transduction process controlling receptor-operated Ca2+ channels or other membrane potential-independent mechanisms involved in pharmacomechanical coupling in smooth muscle.1
Clinical Context
Pharmacomechanical coupling plays a crucial role in the physiological control of penile erection and its dysfunction. Penile erection is a neurovascular phenomenon involving the relaxation of cavernous smooth muscles. The tone of these muscles is modulated by molecular mechanisms dependent on agonists like neurotransmitters and endothelial-derived factors. An increase in intracellular Ca2+ concentration is key for contraction, and its regulation, along with the sensitivity of the contractile machinery, is vital for smooth muscle cell function. While electromechanical coupling also contributes to cavernous smooth muscle contraction, pharmacomechanical coupling, triggered by the binding of agonists to G protein-coupled receptors (GPCRs) and the activation of the inositol cascade, is primarily responsible for maintaining penile flaccidity. This involves the action of noradrenaline (NA) on adrenergic receptors, as well as other mediators like endothelin-1 (ET-1), prostaglandin F2α (PGF2α), thromboxane A2 (TXA2), and angiotensin II (ANG II). Alterations in these cellular signaling pathways within cavernous smooth muscle cells can lead to erectile dysfunction (ED). Therefore, understanding pharmacomechanical coupling is essential for developing new therapeutic approaches for ED.2